» Articles » PMID: 11589831

Systematic Determination of the Packaging Limit of Lentiviral Vectors

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2001 Oct 9
PMID 11589831
Citations 211
Authors
Affiliations
Soon will be listed here.
Abstract

Because of their ability to transduce nondividing cells, human immunodeficiency virus type 1 (HIV)-based vectors have great potential for the therapeutic delivery of genes to cells. We describe here a systematic study of the packaging limit of HIV-based vectors. Restriction endonuclease-generated bacterial chromosomal DNA fragments of different lengths were cloned at three different positions within a lentiviral vector. Vesicular stomatitis virus G protein (VSV G) pseudotyped lentiviral particles were prepared and the different clones were titered on mammalian cells. We observed that the restriction endonuclease site positions at the 5' and 3' ends of the genome were superior with regard to insertional capacity of foreign DNA. In all cases, viral titers decreased semi-logarithmically with increasing vector length. There appears to be no absolute packaging limit because measurable titers were obtained even when the proviral length was in excess of 18 kb. The reduction in titer appears to occur at the level of viral encapsidation, although we cannot exclude limitations in nuclear export of proviral RNA. These results suggest that HIV-based vectors may have a secondary advantage over oncoretroviral vectors because of their greater packaging limit, although the very low titers of the larger vectors will be of limited utility.

Citing Articles

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies.

Zhang C, Liu H J Immunol Res. 2025; 2025():5845167.

PMID: 39844819 PMC: 11753851. DOI: 10.1155/jimr/5845167.


Expression levels and stoichiometry of Hnf1β, Emx2, Pax8 and Hnf4 influence direct reprogramming of induced renal tubular epithelial cells.

Hu X, Sun J, Wan M, Zhang B, Wang L, Zhong T Cell Regen. 2024; 13(1):19.

PMID: 39347883 PMC: 11442758. DOI: 10.1186/s13619-024-00202-0.


Cell and gene therapy in neuro-oncology.

Varela M, Comba A, Faisal S, Argento A, Pena Aguelo J, Candolfi M Handb Clin Neurol. 2024; 205:297-315.

PMID: 39341660 PMC: 11441620. DOI: 10.1016/B978-0-323-90120-8.00009-5.


Neurosurgical gene therapy for central nervous system diseases.

Patel R, Nanda P, Richardson R Neurotherapeutics. 2024; 21(4):e00434.

PMID: 39191071 PMC: 11445594. DOI: 10.1016/j.neurot.2024.e00434.


STRAIGHT-IN: a platform for rapidly generating panels of genetically modified human pluripotent stem cell lines.

Blanch-Asensio A, Grandela C, Mummery C, Davis R Nat Protoc. 2024; .

PMID: 39179886 DOI: 10.1038/s41596-024-01039-2.